GALT

Company Overview — What Does GALECTIN THERAPEUTICS INC Do?

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. GALECTIN THERAPEUTICS INC (GALT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joel Lewis and employs approximately 9 people, headquartered in NORCROSS, Georgia. With a market capitalization of $176M, GALT is one of the notable companies in the Healthcare sector.

GALECTIN THERAPEUTICS INC (GALT) Stock Rating — Reduce (April 2026)

As of April 2026, GALECTIN THERAPEUTICS INC receives a Reduce rating with a composite score of 29.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.GALT ranks #3,651 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, GALECTIN THERAPEUTICS INC ranks #597 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GALT Stock Price and 52-Week Range

GALECTIN THERAPEUTICS INC (GALT) currently trades at $2.26. The stock lost $0.17 (7.0%) in the most recent trading session. The 52-week high for GALT is $7.13, which means the stock is currently trading -68.3% from its annual peak. The 52-week low is $1.12, putting the stock 101.8% above its annual trough. Recent trading volume was 202K shares, suggesting relatively thin trading activity.

Is GALT Overvalued or Undervalued? — Valuation Analysis

GALECTIN THERAPEUTICS INC (GALT) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth.

At current multiples, GALECTIN THERAPEUTICS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

GALECTIN THERAPEUTICS INC Profitability — ROE, Margins, and Quality Score

GALECTIN THERAPEUTICS INC (GALT) earns a quality factor score of 9/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 34.5%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -187.2% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GALT Debt, Balance Sheet, and Financial Health

GALECTIN THERAPEUTICS INC has a debt-to-equity ratio of -73.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.42x, indicating strong short-term liquidity. Total debt on the balance sheet is $90M. Cash and equivalents stand at $12M.

GALT has a beta of 0.55, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for GALECTIN THERAPEUTICS INC is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

GALECTIN THERAPEUTICS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, GALECTIN THERAPEUTICS INC reported revenue of $0 and earnings per share (EPS) of $-0.48. Net income for the quarter was $-37M. Operating income came in at $-26M.

In FY 2025, GALECTIN THERAPEUTICS INC reported revenue of $0 and earnings per share (EPS) of $-0.48. Net income for the quarter was $-31M. Operating income came in at $-20M.

In Q3 2025, GALECTIN THERAPEUTICS INC reported revenue of $0 and earnings per share (EPS) of $-0.13. Net income for the quarter was $-8M. Operating income came in at $-4M.

In Q2 2025, GALECTIN THERAPEUTICS INC reported revenue of $0 and earnings per share (EPS) of $-0.12. Net income for the quarter was $-8M. Operating income came in at $-5M.

Over the past 8 quarters, GALECTIN THERAPEUTICS INC has experienced revenue contraction from $0 to $0. Investors analyzing GALT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GALT Dividend Yield and Income Analysis

GALECTIN THERAPEUTICS INC (GALT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GALT Momentum and Technical Analysis Profile

GALECTIN THERAPEUTICS INC (GALT) has a momentum factor score of 45/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 67/100 reflects moderate short selling activity.

GALT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, GALECTIN THERAPEUTICS INC (GALT) ranks #597 out of 838 stocks based on the Blank Capital composite score. This places GALT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GALT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GALT vs S&P 500 (SPY) comparison to assess how GALECTIN THERAPEUTICS INC stacks up against the broader market across all factor dimensions.

GALT Next Earnings Date

No upcoming earnings date has been announced for GALECTIN THERAPEUTICS INC (GALT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GALT? — Investment Thesis Summary

The quantitative profile for GALECTIN THERAPEUTICS INC suggests caution. The quality score of 9/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. High volatility (stability score 36/100) increases portfolio risk.

In summary, GALECTIN THERAPEUTICS INC (GALT) earns a Reduce rating with a composite score of 29.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GALT stock.

Related Resources for GALT Investors

Explore more research and tools: GALT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GALT head-to-head with peers: GALT vs AZN, GALT vs SLGL, GALT vs VMD.